All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL). ZUMA-2 (NCT02601313) is a phase II study of KTE-X19 in patients with heavily pretreated MCL. The Lymphoma Hub has previously reported on the study design and phase II results of the ZUMA-2 trial. Below, we provide a summary of the 3-year follow-up results as published by Wang, et al., in Journal of Clinical Oncology in 2022.1
As previously reported, 74 patients were enrolled in the trial and 68 patients received treatment with KTE-X19. At the data cutoff, the median follow-up time was 35.6 months. Several high-risk sub-groups were present in the patient population, including patients with blastoid variant, high Ki-67 proliferation index, tumor protein p53 gene mutation16 or high p53 and disease progression within 24 months postdiagnosis. The primary endpoint was the objective response rate (ORR) assessed by independent radiologic review committee. Secondary endpoints were duration of response (DOR), progression-free survival (PFS), overall survival (OS), adverse event (AE) incidence, blood CAR T-cell levels, and serum cytokine levels. Minimal residual disease (MRD) was assessed as an exploratory endpoint. Post-hoc assessment of subgroups was also performed based on prognostic features.1
Figure 1. Responses in the all-treated population*
CR, complete response; ORR, objective response rate; PR, partial response.
*Adapted from Wang, et al.1
At 6 months, 79% of MRD-assessable patients were MRD-negative (ORR, 100%). At the data cutoff, median DOR, PFS, and OS were 6.1, 7.1, and 27 months among the MRD-positive patients, respectively, and MRD negativity at months 3, 6, and 9 was associated with durable response.
In the intention-to-treat population, ORR was 84% (CR, 62%; PR, 22%) and median PFS and OS were 24 months and 47.4 months, respectively. Response rates were stable among prespecified subgroups of prior Bruton’s tyrosine kinase inhibitor exposure or high-risk characteristics. Blood CAR T-cell levels were higher at a median of 15 days post-infusion, with median concentrations plateauing at 0.19–0.34 cells/µL from Month 6–18.
No new safety signals were reported in the long-term follow-up of this trial, with only 3% of all adverse events of interest occurring since the previous data cutoff. AEs of any grade and ≥Grade 3 occurred in 26% and 21% of patients, respectively, and the most frequent AEs included cytopenia (19%), infections (10%), and neurologic events (3%).
This longer-term follow-up of ZUMA-2 study demonstrated the durable long-term effectiveness and safety of KTE-X19 in patients with R/R MCL. In addition, KTE-X19 showed positive responses in patients with high-risk characteristics, such as those with a high Ki-67 proliferation index. Taken together, these results further underline the benefits of KTE-X19 and support further investigations into this treatment protocol.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox